Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
22%
Ph phase_3
1
11%
Ph not_applicable
2
22%
Ph phase_4
3
33%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
3(37.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Completed(1)
Other(4)

Detailed Status

unknown4
Recruiting3
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (25.0%)
Phase 31 (12.5%)
Phase 43 (37.5%)
N/A2 (25.0%)

Trials by Status

unknown444%
recruiting333%
completed111%
not_yet_recruiting111%

Recent Activity

3 active trials
Showing 5 of 9
completedphase_2

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

NCT06139419
recruitingphase_2

Thymosin-α1 for Recurrent Implantation Failure

NCT07675980
recruitingnot_applicable

Immuno-effect of Tα1 for Stage I NSCLC

NCT06598839
unknownphase_4

Thymosin Alpha-1 for irAE Secondary to ICIs

NCT06178146
unknownnot_applicable

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

NCT05487469
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06139419Phase 2

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Completed
NCT07675980Phase 2

Thymosin-α1 for Recurrent Implantation Failure

Recruiting
NCT06598839Not Applicable

Immuno-effect of Tα1 for Stage I NSCLC

Recruiting
NCT06178146Phase 4

Thymosin Alpha-1 for irAE Secondary to ICIs

Unknown
NCT05487469Not Applicable

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Unknown
NCT05086614Phase 3

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Recruiting
NCT04901104

Long-term Prognosis of Patients With Sepsis After Immunotherapy

Not Yet Recruiting
NCT04524169Phase 4

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

Unknown
NCT03448744Phase 4

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9